# Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk

> **NCT04128163** · PHASE3 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 440 (estimated)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** QL1206
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT04128163
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-05
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-12-01
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2019-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128163, "Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04128163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*